This 30-minute RACP accredited activity aims to equip physicians in determining which patients may benefit from preventative migraine therapies such as CGRP inhibitors. Featuring a case study and video interview from Neurologist, Associate Professor Richard Stark.
CGRP Inhibition: A new era in migraine prevention
Australie
$0
gratuit
RACP
0.5 hrs
Neurology, Pain
0.5 Credits
Description du cours
Détails du cours
Date d'expiration : 2022-06-27
Métiers: Spécialiste
Faculté
A/Prof Richard Stark,
AM, MB, BS, FRACP Neurologist
Accréditation
This interactive online learning activity is valued at 0.5 Hour(s) of continuing education.
Objectif(s) d'apprentissage
Upon completion of this program, participants will be able to:
- Understand the positive impact they can have on the quality of life (QOL) of migraine patients through timely intervention/escalation of therapy.
- Understand how the introduction of calcitonin gene related peptide (CGRP) inhibitors has changed the treatment paradigm in migraine prevention.
- Identify patients who could benefit from timely introduction of a CGRP inhibitor.
- Reduce the risk of oral medication overuse in their patients and minimise the unnecessary complexity of managing patients with oral medications.
- Discuss the rapid impact that CGRP inhibitors can have on the QOL of people with migraine.